Cipla Limited and Boehringer Ingelheim India Pvt. Ltd. have announced their partnership in India to co-market three new oral anti-diabetics drugs Oboravo® (Empagliflozin), Oboravo Met® (Empagliflozin+Metformin) and Tiptengio® (Empagliflozin+Linagliptin) As per the International Diabetes Federation, India is home to 77 million adults aged between 20 and 79 years with diabetes, ranking second behind China; and is poised to reach 134.2 million patients by 2045. Fortunately, … Continue reading Three new oral anti-diabetics drugs in India- co-marketed by Cipla & Boehringer Ingelheim

Covid 19 infected Patients suffering from severe respiratory symptoms can rapidly generate an immune response in the form of virus-attacking T cells, suggests a new study which may lead to new vaccine development strategies against COVID-19. The study, published in the journal Science Immunology, assessed T cells from 10 COVID-19 patients under intensive care treatment. According to the researchers, including those from the University of … Continue reading Identified Immune Response Protection Against COVID-19

The approval of ‘COVIFOR’, the generic of Remdesivir by Drugs Controller General of India (DCGI), Hetero Healthcare Limited, a group company of Hetero is set to deliver the first set of 20,000 vials in two equal lots of 10,000 each, one of which, will be immediately supplied to Hyderabad, Delhi, Gujarat, Tamil Nadu, Mumbai and other parts of Maharashtra; while the other lot will be supplied to … Continue reading Covifor is the first generic brand of Remdesivir